Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Costain doubles dividend as FY profit comes in at top end of expectations

(Sharecast News) - Construction engineering firm Costain surged on Tuesday as it reported full-year profit at the upper end of expectations, doubled its dividend and hailed record growth in its forward work position. In the year to the end of December 2024, adjusted pre-tax profit rose 9.7% to £48.5m, while adjusted operating profit was up 7.5% to £43.1m, at the top end of expectations.

Revenue fell 6.1% to £1.25bn due to the timing of contract starts and completions in the transportation segment, with growth in all natural resources sectors.

Costain pointed to a record increase of £1.5bn in its forward work position to £5.4bn, more than four times FY 24 revenue.

The company doubled its full-year dividend to 2.4p a share.

Chief executive Alex Vaughan said: "The record growth in forward work position is expected to deliver further progress in FY 25 and FY 26, followed by a step change in FY 27 performance. The quality, balance and better risk profile of our forward work position of £5.4bn across our two divisions, together with continued investment in our chosen markets, gives us increasing visibility on future revenue and margin.

"We continue to deliver improvements and invest in the business, and are increasingly confident in the group's growth prospects, with our strong cash position and cash generation enabling the group to enhance returns to shareholders."

At 0930 GMT, the shares were up 8.7% at 113p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.